Mdm2 in growth signaling and cancer: Mini review
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Genetic and biochemical evidence have demonstrated a direct link between Mdm2 and cancer development. Elevated expression of Mdm2 is observed in a significant proportion of different types of cancer. The major contribution of Mdm2 to the development of cancer is through a tight inhibition of the activities and stability of the tumor suppressor p53. However, extensive studies over the past few years have identified p53-independent functions of Mdm2, in the regulation of several important cellular processes and multiple signaling pathways. The promotion of cell cycle progression by Mdm2 is mediated via p53 inhibition, and by regulating the pRb/E2F complex. Mdm2 is an important mediator of growth and survival signaling in the PI3K/Akt pathway, an activator of certain steroid hormone receptors, and an inhibitor of the TGF-beta growth restrictive pathway. Thus, the impact on these pathways by deregulated Mdm2, as often observed in cancer, can be oncogenic in a permissible environment. This renders Mdm2 as an important target for the development of anti-cancer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · cited 1×
“The rationale design of inhibitors was made possible through the identification of a hydrophobic binding pocket in Mdm2 that interacts with the p53 transactivation domain (Kussie et al. 1996).”
BackgroundAmplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · cited 1×
“Another interesting angle on the involvement of Hdm2 in cancer has been recently revealed by work from the laboratory of Levine (Bond et al. 2004).”
BackgroundMayo, L. D., & Donner, D. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181181198 · Cited by 1,230
E2F integrates cell cycle progression with DNA repair, replication, and G 2 /M checkpoints
Ren, B., Cam, H., Takahashi, Y., Volkert, T., Terragni, J., Young, R. A., & Dynlacht, B. D. (2002) · Genes & Development · doi:10.1101/gad.949802 · Cited by 1,125
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-973 · Cited by 951 · cited 1×
“Importantly, the nuclear import of Mdm2 is induced with the subsequent inhibition and degradation of p53 (Mayo and Donner 2001, Zhou et al. 2001).”
BackgroundMono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2
Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., & Gu, W. (2003) · Science · doi:10.1126/science.1091362 · Cited by 804 · cited 1×
“Low levels of Mdm2 activity induce mono-ubiquitination and nuclear export of p53, whereas high levels promote polyubiquitination and nuclear degradation of p53 (Li et al. 2003).”
BackgroundMDM2 — master regulator of the p53 tumor suppressor protein
Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641 · cited 2×
“Mdm2 amplification is observed in approximately 7% of all human tumors (Momand et al. 2000), however, the frequency is higher in certain types of cancers such as soft tissue tumors (20%), osteosarcomas (16%) in gliomas (10%) (reviewed in Momand et al.”
BackgroundAkt Enhances Mdm2-mediated Ubiquitination and Degradation of p53
Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T., Tanaka, K., Masuyama, N., & Gotoh, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109745200 · Cited by 617 · cited 1×
“…model are still contented, for example, the identity of the Akt phosphorylation sites on Mdm2 (Ashcroft et al. 2002, Gottlieb et al. 2002, Feng et al. 2004), and the effect of the phosphorylation on the sub-cellular localization of Mdm2 (Ashcroft et al. 2002, Ogawara et al. 2002, Feng et al. 2004).”
BackgroundOpposing Effects of Ras on p53
Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M., & McCormick, F. (2000) · Cell · doi:10.1016/s0092-8674(00)00123-9 · Cited by 357
Cited by
Mdm2-mediated ubiquitylation: p53 and beyond
Marine, J.-C., & Lozano, G. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.68 · Cited by 354
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
Moran, D. M., & Maki, C. G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1220 · Cited by 35
“MDM2 is an E3 ligase that binds to and ubiquitinates p53, leading to its proteasomal degradation (5, 6).”
BackgroundHdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells
Sui, X., Shin, S., Zhang, R., Firozi, P. F., Yang, L., Abbruzzese, J. L., & Reddy, S. A. G. (2009) · Oncogene · doi:10.1038/onc.2008.423 · Cited by 25
Metadata
- Authors
- Levav-Cohen, Y., Haupt, S., & Haupt, Y.
- Venue
- Growth Factors
- Publisher
- Informa UK Limited
- Published
- 2005-01
- Volume
- 23
- Issue
- 3
- Pages
- 183-192
- ISSN
- 0897-7194 (ISSN-L)
- 1029-2292
- OpenAlex
- W1875794575
- Cited by
- 60
- References
- 16
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mdm2 in growth signaling and cancer: Mini review. https://app.cochat.ai/papers/10.1080/08977190500196218
- The paper
- Levav-Cohen, Y., Haupt, S., & Haupt, Y. (2005). Mdm2 in growth signaling and cancer: Mini review. Growth Factors. https://doi.org/10.1080/08977190500196218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.